Promoting Global Partnerships for Rasmutinib and PHI-501 Based on Chemiverse Platform

Rasmutinib Shows Complete Remission Response in Phase 1b Trial... Preparing for Global Phase 2

Pharos iBio, a company specializing in artificial intelligence (AI)-based drug discovery, announced on June 15 that it will participate in the 2026 BIO International Convention (BIO USA), which will be held in San Diego, U.S., from June 22 to 25. The company aims to promote global business development for its AI-driven oncology drug pipeline at the event.


Pharos iBio company logo image. Pharos iBio

Pharos iBio company logo image. Pharos iBio

View original image

Pharos iBio was selected as a corporate presentation (IR) pitching company at this event and will introduce its main pipeline and research achievements, based on its AI drug discovery platform 'Chemiverse,' to global pharmaceutical and biotechnology companies, as well as investors.


The main candidates to be introduced include Rasmutinib (PHI-101), a potential treatment for acute myeloid leukemia (AML), and PHI-501, a candidate for treating refractory solid tumors.


Rasmutinib demonstrated a composite complete remission rate (CRc) of 50% in a Phase 1b clinical trial for patients with relapsed or refractory AML. The company is currently preparing to enter a global Phase 2 clinical trial. Rasmutinib has already received orphan drug designation in Korea, the United States, and Europe.


PHI-501 is being developed as a treatment for solid tumors, such as colorectal cancer, melanoma, and lung cancer, based on a dual inhibition mechanism that simultaneously targets BRAF, KRAS, and NRAS mutations. In January of this year, the company began dosing the first patient in a Phase 1 clinical trial in Korea and is currently evaluating the possibility of combination therapy with immune checkpoint inhibitors.


At BIO USA, Pharos iBio plans to discuss technology transfer and joint research collaborations with global pharmaceutical companies. In addition, it will introduce its follow-up oncology pipeline, including the next-generation EGFR inhibitor 'PHI-701' and the menin inhibitor 'PHI-601,' both of which are being co-developed with Kolon Pharmaceutical.



Kyutae Kim, Chief Business Development Officer at Pharos iBio, stated, "Through BIO USA, we will share the development achievements of our main pipeline and expand opportunities for global partnerships."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing